Skip to content
Whale Atlas — Follow the signal.
Home
FULL RECORDS
All Congress filingsSearch insider filings
MORE TOOLS
WatchlistGold IntelligenceSilver IntelligencePeopleCharts & technicalsCompany financialsOfficial newsMy saved workspace
YOUR RESEARCH
HomeAll Congress filingsSearch insider filings
More research tools
ExploreGold IntelligenceSilver IntelligencePeopleInvestigate an ideaCharts & technicalsMore evidenceCompany financialsOfficial newsMy research & helpWatchlistMy saved workspaceLearn the basicsHow signals workData & coverage
RESOURCES
LearnMethodologyData sources
Built on public evidence.

Primary sources. Clear reasoning.
No black boxes.

Our approach
Public research workspacev1.0

Loading data…

HomeSearchCongressWatchlist
© 2026 Whale AtlasFree public-filing research. Not financial advice. By using this site you agree to the Terms of Use.
FAQCompare trackersMethodologyData & correctionsTermsPrivacy
LOOK INSIDE THE BUSINESS

Company financials.

Explore company-wide revenue, income and balance-sheet facts directly from SEC filings.

View SPRY insider activity ↗

SPRYARS Pharmaceuticals, Inc.

THE LATEST REPORTED YEAR

The company reported a loss.

$171.3M net loss for the year ended December 31, 2025. These are reported results, not a forecast or a stock recommendation.

Revenue$84.28MYear ended December 31, 2025
Profit or loss-$171.3MYear ended December 31, 2025
Cash from the business-$170.87MYear ended December 31, 2025
Total assets$249.5MAs of June 30, 2026
Total liabilities$236.98MAs of June 30, 2026
Cash & equivalents$8.16MAs of June 30, 2026
THE BUSINESS BEHIND THE TICKER

Revenue, over time.

Latest-filed standard financial facts · USD

$5.51M
2021-12
$1.32M
2022-12
$30K
2023-12
$89.15M
2024-12
$84.28M
2025-12

Bars show magnitude; labels retain the sign. Each observation covers a reported annual period of 330–400 days; transition years can differ.

From the filing

Reported periods can differ from calendar years. Later filings may restate earlier figures. These are company-wide facts; product and geographic revenue segments are not included.

Reported periodReported valueFiledSource
January 1, 2025 – December 31, 2025$84,278,000March 9, 202610-K ↗
January 1, 2024 – December 31, 2024$89,149,000March 9, 202610-K ↗
January 1, 2023 – December 31, 2023$30,000March 20, 202510-K ↗
January 1, 2022 – December 31, 2022$1,316,000March 21, 202410-K ↗
January 1, 2021 – December 31, 2021$5,506,000March 23, 202310-K ↗
Source and calculation details

One standard US-GAAP or IFRS concept is selected per metric, using USD only. Annual durations must be 330–400 days. Quarterly durations must be 70–110 days; year-to-date totals are excluded, and fourth quarters are never inferred by subtraction. Cash-flow quarters can therefore be sparse. Conflicting values filed on the same day are excluded. Latest-filed values are used, so these observations must not be treated as facts known in an earlier backtest.

Concept: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · Retrieved October 12, 2026

Response SHA-256: 2c5a7142d269b28831cca7ac1261f0995af95a67f581ad2648504d2117d943c8

SEC company facts

Company-wide USD figures from SEC filings. Each card keeps its own reporting date; later filings can revise earlier results.